Anthony Giovinazzo

Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada.

ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL.

Neurotrophic Bioscience, Inc. develops pharmaceutical products.

Part of SignalEnergy, Inc., Nova Molecular, Inc. develops pharmaceutical products. The company is based in Montréal, Canada.

The Institute of Corporate Directors is a not-for-profit, member-based association that serves as a resource and voice for directors and boards. The non-profit company is based in Toronto, Canada, and has subsidiaries in Canada. The ICD provides thought leadership through various publications and is a unified voice for directors. The Canadian company was founded by Brian J. Gibson, and Rahul K. Bhardwaj has been the CEO of the company since 2016.

Cervelo Pharmaceuticals Ltd. engages in the preparation of pharmaceuticals. It develops drug product candidates for neuropathic, inflammatory, and neurodegenerative diseases. The company was founded by Anthony J. Giovinazzo in 2006 and is headquartered in Mississauga, Canada.

Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland.

Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada.

Sunovion CNS Development Canada Ulc develops pharmaceuticals products. The company is headquartered in Vancouver, Canada.

Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada.

Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.